Minirin (Desmopressin)

Desmopressin mimics the natural hormone vasopressin and selectively activates V2 receptors in the kidney’s collecting ducts. This triggers a cascade that increases cyclic AMP, leading to the insertion of aquaporin‑2 channels and enhanced water reabsorption. In blood vessels, it promotes release of clotting factors, aiding haemostasis.

The dosage of Minirin is individualized. A qualified prescriber determines the appropriate strength, frequency, and duration based on the patient’s specific condition, age, renal function, and response to therapy. Patients should follow the prescribing information provided by their healthcare professional.

Desmopressin’s pregnancy category is listed as unknown, and safety data are limited. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their physician before starting Minirin. The prescriber will weigh the therapeutic need against any possible fetal or infant exposure.

To request Minirin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature‑controlled requirements), and necessary import documentation.

Minirin (desmopressin) is a synthetic vasopressin analogue with high selectivity for V2 receptors, offering a longer duration of action and fewer vasoconstrictive effects than natural vasopressin. Compared with other antidiuretic agents, it provides more predictable dosing and is available in convenient sublingual and nasal forms, making it a preferred option for many clinicians.

Minirin should be stored at room temperature, below 25 °C. Keep the tablets in their original blister pack, protect them from moisture and direct sunlight, and avoid storing them in bathrooms or other humid environments to maintain potency.

Minirin is supplied as a sublingual tablet. The tablet is placed under the tongue and allowed to dissolve completely without chewing or swallowing whole. Patients should avoid eating or drinking for a few minutes after administration to ensure optimal absorption.

The most critical safety concerns are severe hyponatremia and water intoxication, which can lead to seizures, cerebral edema, or coma. Patients must be monitored for rapid drops in serum sodium, especially when fluid intake is excessive or when the drug is combined with other antidiuretic agents.

Minirin is contraindicated in individuals with known hypersensitivity to desmopressin, uncontrolled hyponatremia, severe renal impairment, or active pulmonary edema. Caution is also advised for patients with uncontrolled hypertension or those taking interacting medications that increase the risk of water retention.